Brief: TC Biopharm Intends To Launch Preclinical Studies For Treatment Of Monkey Pox
06/09/2024 21:27
Sept 6 (Reuters) - TC Biopharm (Holdings) PLC T0U0y.F :
* TC BIOPHARM INTENDS TO LAUNCH PRECLINICAL STUDIES FOR
TREATMENT
OF MONKEY POX
* TC BIOPHARM LTD - INTENDS TO BEGIN PROOF OF CONCEPT
PRECLINICAL
STUDIES FOR ITS LEAD THERAPEUTIC TCB 008, FOR TREATMENT IN
MONKEY POX
Source text for Eikon: ID:nPn7N6Snra
Further company coverage: T0U0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TC Biopharm (Holdings)
See all newsBrief: Cytomed Therapeutics Completes Acquisition Of T Cell Technology From Uk To Treat Cancers In China And India
Brief: TC BioPharm Announces Complete Response In Minimal Residual Disease Patient
Brief: TCBP Announces Non-Binding Letter Of Intent To Acquire Commercial Stage Ophthalmic Pharmaceutical Company
Brief: TC Biopharm's Data Show A Favorable Response In Patients With Relapse Or Refractory AML
Brief: TCBP Trading Continues Unabated On Nasdaq Stock Exchange